Overweight or obese adults lost more weight and shed pounds faster using Eli Lilly s Mounjaro than those taking Novo Nordisk s popular rival weight loss drug.
Novo Nordisk has announced a $2.3 billion investment to boost production of its wildly popular weight-loss and diabetes drugs at a site in Chartres, France.
Novo Nordisk will launch its hugely popular anti-obesity drug in Japan on February 22, its first launch in Asia, even as it struggles to keep up with demand in existing markets.
Unlike tirzepatide, which combines weight loss and glucose-lowering properties, this twincretin reduces liver fat along with weight, blood pressure, and lipid levels.